Text Size
2 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Carcinoma, Endometrioid"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
2 Unknown † Intraperitoneal Paclitaxel, Doxorubicin, and Cisplatin in Treating Patients With Endometrial Cancer
Conditions: Endometrial Cancer;   Ovarian Cancer
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
To Top

† Indicates status has not been verified in more than two years